Monopar Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Updates
First Patient Dosed in Validive
®
Camsirubicin Run-in Clinical Trial Now Planned to Start in 2H 2021
Potential Utility Reported for MNPR-101 as Imaging Agent in Cancer Surgery
WILMETTE, Ill., May 13, 2021 (GLOBE NEWSWIRE) Monopar Therapeutics Inc. (Monopar or the Company) (Nasdaq: MNPR), a clinical-stage biopharmaceutical company primarily focused on developing proprietary therapeutics designed to extend life or improve the quality of life for cancer patients, today announced first quarter 2021 financial results and recent business updates.
Recent Business Updates
Validive
Monopar’s Phase 2b/3 VOICE clinical trial of Validive (clonidine HCl mucobuccal tablet) for the prevention of severe oral mucositis (SOM) in patients undergoing chemoradiotherapy (CRT) for oropharyngeal cancer (OPC) dosed its first patient in February 2021 and is actively recruiting patients and initiating ad
New London, CT (PRWEB) May 12, 2021 Respected periodontists, Dr. Gregory Toback and Dr. Marianne Urbanski offer bone grafting in New London, CT, helping
Pregnant women hospitalised for COVID-19 infection do not face increased death risk: Study ANI | Updated: May 12, 2021 13:26 IST
Washington [US], May 12 (ANI): Pregnant women who develop severe COVID-19infections that require hospitalisation for pneumonia and other complications may not be more likely to die from these infections than non-pregnant women.
In fact, they may have significantly lower death rates than their non-pregnant counterparts. The study, conducted by researchers at the University of Maryland School of Medicine (UMSOM), was published in the journal Annals of Internal Medicine .
The study examined medical records from nearly 1,100 pregnant women and more than 9,800 non-pregnant patients aged 15 to 45 who were hospitalised with COVID-19 and pneumonia. Slightly less than 1 per cent of the pregnant patients died from COVID-19 compared to 3.5 per cent of non-pregnant patients, according to the study findings.
Severe COVID-19 infections in pregnant women do not increase risk of death
Pregnant women who develop severe COVID-19 infections that require hospitalization for pneumonia and other complications may not be more likely to die from these infections than non-pregnant women. In fact, they may have significantly lower death rates than their non-pregnant counterparts. That is the finding of a new study published today in the
Annals of Internal Medicine conducted by researchers at the University of Maryland School of Medicine (UMSOM).
The study examined medical records from nearly 1,100 pregnant women and more than 9,800 non-pregnant patients aged 15 to 45 who were hospitalized with COVID-19 and pneumonia. Slightly less than 1 percent of the pregnant patients died from COVID-19 compared to 3.5 percent of non-pregnant patients, according to the study findings.
Study explores COVID-19 infection in pregnant women
ANI
12 May 2021, 19:55 GMT+10
Washington [US], May 12 (ANI): Pregnant women who develop severe COVID-19 infections that require hospitalisation for pneumonia and other complications may not be more likely to die from these infections than non-pregnant women.
In fact, they may have significantly lower death rates than their non-pregnant counterparts. The study, conducted by researchers at the University of Maryland School of Medicine (UMSOM), was published in the journal Annals of Internal Medicine .
The study examined medical records from nearly 1,100 pregnant women and more than 9,800 non-pregnant patients aged 15 to 45 who were hospitalised with COVID-19 and pneumonia. Slightly less than 1 per cent of the pregnant patients died from COVID-19 compared to 3.5 per cent of non-pregnant patients, according to the study findings.